Citi Puts Agilent on 90-Day Catalyst Watch with $185 Target
Citi placed Agilent Technologies on a 90-day catalyst watch with a $185 price target, expecting the Biocare Medical acquisition to clear share overhang and boost valuation multiples. Jim Cramer cautioned that post-pandemic equipment saturation in life sciences has left Agilent’s growth choppy, likening its performance slump to Danaher’s.
1. Catalyst Watch and Price Target
Analysts at Citi placed Agilent Technologies on a 90-day catalyst watch and maintained a Buy rating with a $185 price target, citing an expected rebound in valuation multiples once near-term catalysts emerge.
2. Biocare Medical Acquisition Details
The potential transformational acquisition of Biocare Medical is expected to remove the share overhang, enhance Agilent’s presence in diagnostics and drive revenue growth from specialized medical testing instruments.
3. Cramer’s Assessment of Post-Pandemic Performance
Jim Cramer highlighted that life sciences equipment saturation following the pandemic has led to choppy stock performance, comparing Agilent’s post-COVID slowdown to the decline experienced by Danaher.